HTFL heartflow.com: Forward Price-to-Revenue Multiple

HeartFlow Inc (HTFL) holds a leading position in AI-driven blood flow analytics, benefiting from high trust among global cardiologists. The company's forward P/S dynamics reflect its real-time market valuation, where 24.50 determines the current status of the parameter. Growth potential is driven by strong data scientists and close partnerships with clinics to implement cloud-based non-invasive diagnostic services.

HTFL (HeartFlow) Forward Price to Sales history from 08/09/2025 to 11/13/2026

HeartFlow Medical - analytical breakdowns and key metrics (HTFL)

- market price and analyst price targets:

Price Chart HeartFlow Inc|HTFL - Average Forecast Price

- company stock capitalization data:

Market Valuation HeartFlow Medical|HTFL - Real Price to Acquire Entire Company

- business book valuation details:

Accounting Value per Share HeartFlow|HTFL - Accounting Value of Company|Market Capitalization to Book Value Ratio heartflow.com|HTFL - Company Total Asset Base

- debt level and financial liquidity data:

- net income and valuation multiples indicators:

HTFL - Profit After Tax|Expected Profit Heartflow Inc|HTFL - Price to Earnings Ratio|Forward P/E Multiple HeartFlow, Inc.|HTFL - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple HeartFlow Medical|HTFL - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) HeartFlow|HTFL - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months heartflow.com|HTFL - Earnings per share increase in current year|Expected earnings per share growth for next year Heartflow Inc

- company sales and revenue statistics:

HTFL - Company Total Sales|Projected Sales Volume HeartFlow Medical|HTFL - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple HeartFlow Medical

Analysis of all company metrics:HeartFlow HTFL

Forward P/S measures the market premium for business scalability potential by relating current market capitalization to projected sales volume. Analyzing the forward P/S of the business allows for the rapid adjustment of the valuation of Heartflow Inc (HTFL) upon the release of quarterly reports, reflecting market confidence in the expansion of cloud-based AI services for ischemia diagnostics and the monetization efficiency of high-tech medical tests.

Key competitors

Price-to-Projected Revenue Ratio Regeneron REGN|iRhythm Technologies, Inc. (IRTC) - Market Cap to Future Revenue Ratio|LNTH: Forward Price-to-Revenue Multiple|Mineralys Corp (MLYS) - Forward Price-to-Revenue Multiple|KMTS (Kestra Medical Technologies) - Forward Price-to-Revenue Multiple|esperion.com - Forward Price to Sales|AMRN (Amarin) - Forward P/S Multiple|Anteris Technologies Ltd (AVR) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Tenaya Therapeutics (TNYA)|CVRx Inc - Market Cap to Projected Revenue|Forward P/S Multiple MIST (Milestone Pharmaceuticals)|CRDL - Forward Price-to-Revenue Multiple|HeartBeam - Forward P/S Multiple|Forward Price to Sales TENX (Tenax Therapeutics Inc.)|ADGM (Adagio Medical Holdings Inc.) - Forward Price-to-Revenue Multiple|BCDA: Price to Expected Revenue Ratio|VTAK (Catheter Precision) - Forward P/S Multiple|ARCA Bio - Future Price to Revenue|Price-to-Projected Revenue Ratio Acasti Pharma (ACST)|Price-to-Projected Revenue Ratio AVTE (Aerovate Therapeutics Inc.)|Forward P/S Multiple VERV (Verve Therapeutics, Inc.)|Forward Price to Sales WINT